REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

04/07/2018 07:06

RNS Number : 4867T
OptiBiotix Health PLC
04 July 2018
 


4 July 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Directorate change
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announces that Dr Sofia Kolyda has been appointed as Director of Research & Development to the Company. Dr Kolyda will take up her position on the Board of OptiBiotix with immediate effect.
 
Dr Kolyda's expertise has been important in the development of OptiBiotix's technology through laboratory studies, human studies and manufacturing scale up which has allowed the Company to create a rich pipeline of award winning products. Sofia's scientific leadership was key to OptiBiotix's winning best scientific publication at ProBiota 2017 and 2018. These awards raise OptiBiotix's profile and reputation, attract commercial interest in our technology and products and provide the scientific evidence base to demonstrate health benefits in support of product commercialisation. 
 
Under Dr Kolyda's leadership, OptiBiotix has established itself as a global leader in targeted microbiome modulation, natural high intensity sweeteners and sweet healthy fibres (SweetBiotix®). This work has led to agreements with a number of global corporates including Tata for microbiome modulation (LPGOS), and two SweetBiotix® agreements, the first with one of the world's largest suppliers of nutritional products and the second with one of the world's largest providers of dairy products.
 
Given the high level of interest in SweetBiotix® and the potential for further partnerships, Dr Kolyda will take on responsibility for leading development programmes with current and future corporate partners. 
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Dr Sofia Kolyda (aged 45):
 




Current Appointments


Appointments in the last 5 years




 


 




None


None




 


 




 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to recognise the significant contribution Sofia has made in the development of OptiBiotix's science into award winning products by offering her a position on the Board. Given the high level of interest we are seeing in our microbiome modulating and SweetBiotix® technologies, this appointment provides Board leadership to enable OptiBiotix to meet multiple partner needs and to fully exploit all opportunitie in this area of growing industry and commercial interest."
 
 
 
For further information, please contact:
 




 


www.optibiotix.com




 


Contact via Walbrook below




 


 




Cairn Financial Advisers LLP


Tel: 020 7213 0880




Liam Murray / Jo Turner


 




 


 




finnCap Broker


Tel: 020 7220 0500




Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)


 




Abigail Wayne (Corporate Broking)


 




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001



 
 
 



 
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEXLFBVDFFBBV